Warfarin for prevention of stroke: A practical, clinical review

Neurologist

Volumn 2, Issue 6, 1996, Pages 319-341

  Hart, Robert G ^a,d   Talbert, Robert L ^b   Kadri, Kathie ^c   Amato, Mary ^a  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c University Health System   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cerebral embolism; Cerebrovascular disease; Intracerebral hemorrhage; Warfarin

Indexed keywords

EID: 2642677031     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet treatment. Part 1. BMJ 1994;308:81-106.
2. European Stroke Prevention Study Working Group. Secondary stroke prevention: Aspirin/dipyridamole combination is superior to either agent alone and to placebo [abstract]. Stroke 1996;27:195.
3. The CATS Group. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
4. Campbell MH. Basilar artery syndrome. Can Med Assoc J 1953;69: 314-5.
5. Wright IS, McDevitt E. Cerebral vascular diseases: Their significance, diagnosis and present treatment, including the selective use of anticoagulant substances. Ann Intern Med 1954;41:682-98.
6. Millikan CH, Siekert RG, Shiek RM. Studies in cerebrovascular disease. Part III. The use of anticoagulant drugs in the treatment of insufficiency of thrombosis within the basilar arterial system. Proc Staff Meet Mayo Clinic 1955;30:116-26.
7. Millikan CH, Siekert RG, Shiek RM. Studies in cerebrovascular disease. Part V. The use of anticoagulant drugs in the treatment of insufficiency of the internal carotid arterial system. Proc Staff Meet Mayo Clin 1955;30:578-86.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154;1449-57.
9. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-62.
10. Anderson DC. How Twin Cities' neurologists treat ischemic stroke. Policies and trends. Arch Neurol 1993;50:1098-103.
11. Miller VT, Feinbert WM, Pearce LA, Rothrock JF, Anderson DC, Hart RG. Effect of antithrombotic therapy on stroke subtypes in atrial fibrillation. Neurology 1996;46:238-40.
12. Antiplatelet Trialist Collaborations. Collaborative overview of randomized trials of antiplatelet treatment. Part III. BMJ 1994;308:235-46.
13. IS1S-2 (Secondary International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
14. Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, et al. A comparison of aspirin with placebo in patients treated with warfarin and heart valve replacement. N Engl J Med 1993;329:524-9.
15. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measurements of the consequences of treatment. N Engl J Med 1988;318:1728-33.
16. Smith P, Arneson H, Holme I. The effect of warfarin on mortality and re-infarction after myocardial infarction. N Engl J Med 1990; 323:147-52.
17. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effects of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;1:499-503.
18. Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet 1982;1:64-8.
19. Baker RN, Broward JA, Fang HC, fisher CM, Groch SN, Heyman A, et al. Anticoagulant therapy in cerebral infarction. Neurology 1962;12: 823-35.
20. Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease. Part II. Neurology 1961;11:132-8.
21. Baker RN, Schwartz WS, Rose AS. Transient ischemic attacks: A report of a study on anticoagulant therapy. Neurology 1966;16:841-7.
22. Pearce JMS, Gubbay SS, Walton J. Long-term anticoagulant therapy in transient cerebral ischemic attacks. Lancet 1965;1:6-9.
23. Brust JCM. Transient ischemic attacks: Natural history and anticoagulation. Neurology 1977;27:701-7.
24. Jonas S. Anticoagulant therapy in cerebrovascular disease: Review and meta-analysis. Stroke 1988;19:1043-8.
25. Hirsh J. Is the dose of warfarin prescribed by American physicians unnecessarily high? Arch Intern Med 1987;147:769-71.
26. Garde A, Samuelsson K, Fahlgren H, Hedberg E, Hjerne L-J, Ostman J. Treatment after transient ischemic attacks: A comparison between anticoagulant drug and inhibition of platelet aggregation. Stroke 1983;14:677-81.
27. Olsson J, Brechter C, Bäcklund H, Krook H, Muller R, Nitelius E, et al. Anticoagulant vs. antiplatelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke 1980;11:4-9.
28. Burén A, Ygge J. Treatment program and comparison between anticoagulants and platelet aggregation inhibitors after transient ischemic attack. Stroke 1981;12:578-80.
29. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995;45:1488-93.
30. Whisnant JP, Cartlidge NE, Elveback LR. Carotid and vertebral-basilar transient ischemic attacks: Effect of anticoagulants, hypertension, and cardiac disorders on survival and stroke occurrence. A population study. Ann Neurol 1978;3:107-15.
31. Eriksson SE, Link H. Evaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit. Acta Neurol Scand 1983;68:96-106.
32. Bousser MG, Eschwege E, Haguenau H, Lefaucconnier JM, Thibult N, Touboul D, et al. AICLA-controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;14:5-14.
33. Sivenius J, Riekkinen PJ, Smets P, Laakso M, Lowenthal A. The European Stroke Prevention Study: Results by arterial distribution. Ann Neurol 1991;29:596-600.
34. Bamford J, Sandercock P, Dennis M, Warlow C, Burn J. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
35. Algra A for the SPIRIT Investigators. Bleeding complications in patients after cerebral ischemia treated with anticoagulant drugs: Preliminary results of SPIRIT [abstract]. Cerebrovasc Dis 1996;6(Suppl 2):77.
36. Grotta JC, Norris JW, Kamm TB, and the TASS Baseline and Angiographic Data Subgroup. Prevention of stroke with ticlopidine. Who benefits most? Neurology 1992;42:111-5.
37. Rothrock JF, Hart RG. Ticlopidine use and threatened stroke. West J Med 1994;160;43-7.
38. Caplan LR. Diagnosis and treatment of ischemic stroke. JAMA 1991;266:2413-8.
39. Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: Does bleeding outweigh the benefit? J Intern Med 1995;237:323-9.
40. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1989;46:727-43.
41. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22:983-8.
42. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology 1993;43: 32-6.
43. Bogousslavsky J, Van Meile G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with atrial fibrillation: The Lausanne Stroke Registry. Neurology 1990;40:1046-50.
44. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC, et al., on behalf of the SPAF Investigators. Carotid stenosis in patients with atrial fibrillation: Prevalence, risk factors and relationship to stroke. Arch Intern Med 1994;154:1372-7.
45. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. The prevalence of atrial fibrillation: Analysis and implications. Arch Intern Med 1995;155:469-73.
46. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I: Clinical features in patients at risk. Ann Intern Med 1992;116:1-5.
47. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II: Echocardiographic features in patients at risk. Ann Intern Med 1991;1:6-12.
48. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism during aspirin therapy in atrial fibrillation. J Stroke Cerebrovasc Dis 1995;5:147-57.
49. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications of chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989;1:175-9.
50. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527-39.
51. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet 1994;343:687-91.
52. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
53. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
54. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
55. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in atrial fibrillation. Arch Intern Med 1996;156:409-16.
56. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
57. van der Meer FJM, Rosendaal FR, Van den Broucke JP, Briet E. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993;153:1557-62.
58. Cannegieter SC, Rosendaal FR, Wintzen AK, van der Meer FJM, Van den Broucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
59. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl Med J 1996;335:540-6.
60. Stroke Prevention in Atrial Fibrillation Investigators. Superiority of adjusted-dose warfarin over low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet. 1996; 348:633-8.
61. Andersen HR, Thuesen L, Bagger JP, Vesterlundt T, Thomsen PE. Prospective randomized trial of atrial vs. ventricular pacing in sicksinus syndrome. Lancet 1994;344:1523-8.
62. Sgarbossa EB, Pinski SL, Maloney JD, Simmons TW, Wilkoff BL, Castle LW, et al. Chronic atrial fibrillation and stroke in paced patients with sick-sinus syndrome. Circulation 1993;88:1045-53.
63. Tanne D, Goldbourt U, Zion M, Reicher-Reiss H, Kaplinsky E, Behar S. Frequency and prognosis of stroke/TIA among 4,808 survivors of acute myocardial infarction. Stroke 1993;24:1490-5.
64. Bodenheimer MM, Sauer D, Shareef B, Brown MW, Fleiss JL, Moss AJ. Relation between myocardial infarct location and stroke. J Am Coll Cardiol 1993;24:61-6.
65. Martin R, Bogousslavsky J, for the Lausanne Stroke Registry Group. Mechanisms of late stroke after myocardial infarct. J Neurol Neurosurg Psychiatry 1993;56:760-4.
66. EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-8.
67. Loh E, St. John Sutton M, Wun C-C, Moyé LA, Rouleau JL, Flaker GC, et al. Ventricular dysfunction predicts cerebrovascular and arterial thromboembolic events following myocardial infarction. Circulation 1995;92(Suppl):1-483.
68. Dunkman WD, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation 1993;87(Suppl VI):94-101.
69. Baker DW, Wright RF. Management of heart failure. IV: Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. JAMA 1994;272:1614-8.
70. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1995;108(Suppl):371S-9S.
71. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke: A selective review. Stroke 1990;21:1111-2.
72. Horowitz DR, Tuhrim S, Rand RH, Danque POV. Stroke secondary to carotid occlusion in a young man with nephrotic syndrome: Case description and review of the literature. J Stroke Cerebrovasc Dis 1992;2:26-33.
73. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
74. Brey RL, Escalante A. Antiphospholipid antibodies, cerebrovascular disease and Sneddon's syndrome. In: Asherson RA, Cervera R, Piette JC, Schonfeld Y, editors. The antiphospholipid syndrome. Boca Raton, FL: CRC Press, 1996:133-50.
75. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac T, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:148-52.
76. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubery P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for stroke in patients less than 55 years of age. Stroke 1993;24:1865-73.
77. Gautier JC, Durr A, Lascault G, Grosgogeat Y. Paradoxical cerebral embolism with a patent foramen ovale. Cerebrovasc Dis 1991;1: 193-202.
78. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Meile G. Stroke recurrence in patients with patent foramen ovale: The Lausanne Study. Neurology 1996;46:1301-6.
79. Saver JL, Easton JD, Hart RG. Dissections and trauma of cerebrocervical arteries. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke: Pathophysiology, diagnosis and management. New York: Churchill-Livingstone, 1992:678-88.
80. Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994;44:2020-7.
81. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474-9.
82. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Am J Cardiol 1994;74:657-61.
83. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, et al. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. Am J Cardiol 1983;51:1537-41.
84. Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro K. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976;72:127-9.
85. Dale J, Myhre E, Loew D. Bleeding during acetylsalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement. Am Heart J 1980;99:746-51.
86. Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: A study in 3,166 outpatients. J Intern Med 1994;236: 299-304.
87. Majerus PW, Broze GJ Jr, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. McGraw-Hill, New York, 1996:1341-59.
88. Mostero JJ, Thijssen HHW. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady state S-warfarin conditions in rat. J Pharmacol Exp Ther 1992;260: 1081-5.
89. Hirsh J, Dalen JE, Deykin K, Poller L, Bussey H. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(Suppl);231-46.
90. Sawyer WT. Warfarin. In: Mungall DG, editor. Applied clinical pharmacokinetics. New York: Raven Press, 1983:187-222.
91. Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc., 1995:285-329.
92. Wells PS, Holbrook AM, Crowther NR, Hirsh J. The interaction of warfarin with drugs and food: A critical review of the literature. Ann Intern Med 1994;121:676-83.
93. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc., 1992:31-46.
94. Zhang Z, Fasco MJ, Huang Z, Guengevich FP, Kaminsky LS. Human cytochromes P4501A1 and P4501AS2: R-warfarin metabolism as a probe. Drug Metab Dispos 1995;23:1339-45.
95. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
96. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-5.
97. Mungall D, Craw-ford M, Hawkins D, Talbert RL, Ludden TM. Population kinetics of warfarin. J Pharmacokinet Biopharm 1985;13: 213-27.
98. Dalmady-Israel C, Talbert RL, Ludden TM, Davis PJ, Wong YWJ, Crawford MH. Steady state kinetics of R and S warfarin in different age groups. Drug Intell Clin Pharm 1986;20:472.
99. Diab F, Feffer S. Hereditary warfarin resistance. S Med J 1994;87: 407-9.
100. Hallak HO, Wedlund PJ, Modi MW, Patel IH, Lewis GL, Woodruff B, et al. High clearance of S warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993;35:327-30.
101. White RH, McKittrick T, Takakuwa J, Callahan C, McDonnell M, Fihn S. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med 1996;156:1197-201.
102. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87;144-52.
103. O'Reilly R, Aggeler P. Studies on coumarin anticoagulant drugs: Initiation of warfarin therapy without a loading dose. Circulation 1968;38:169-77.
104. Hornig CR, Domdorf W, Agnoli AL. Hemorrhagic cerebral infarction: A prospective study. Stroke 1986;17:179-85.
105. Homig CR, Bauer T, Simon C, Trittmacher S, Domdorf W. Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke 1993;24:465-8.
106. Hart RG, Easton JD. Hemorrhagic infarcts. Stroke 1986;17:586-9.
107. Cerebral Embolism Study Group. Cardioembolic stroke, immediate anticoagulation and brain hemorrhage. Arch Intern Med 1987;147: 636-40.
108. Pessin MS, Estol CJ, Lafranchise F, Caplan LR. Safety of anticoagulation after hemorrhagic infarction. Neurology 1993;43:1298-303.
109. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(Suppl):276-90.
110. Landefeld CS, Beyth RJ. Anticoagulation-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-28.
111. Fihn SD, McDonnell M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation: A multicenter study. Ann Intern Med 1993;118:511-20.
112. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996:124; 970-9.
113. Rodvold DA, Erdman S, Friedenberg W. Thromboembolic disorders. In: DiPiro JT, Talbert RL, Wells B, Yee GC, Matzke G, Posey LM, editors. Pharmacotherapy: A pathophysiologic approach. 3rd ed. Stamford, CT: Appleton-Lange, Inc., 1996.
114. Hall JAG, Paul RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122-40.
115. Iturbe-Alessio I, Fonseca MC, Mutchnik O. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986;315:1390-3.
116. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995;108(Suppl):305-11.
117. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471-7.
118. Forsting M, Mattle HP, Huber P. Anticoagulation-related intracerebral hemorrhage. Cerebrovasc Dis 1991;1:97-102.
119. Wintzen AR, De Jonge H, Loeliger EA, Botts GTAM. The risk of intracerebral hemorrhage during oral anticoagulant treatment. Ann Neurol 1984;16:533-58.
120. Franke CL, De Jonge J, van Swieten JC, Op de Coul AAW, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990;21:726-30.
121. Fogelholm R, Eskola K, Kiminkinen T, Kunnamo I. Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neurol Neurosurg Psychiatry 1992;55:1121-4.
122. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989;225:137-42.
123. Link H, Lebram G, Johansson I, Rádberg C. Prognosis in patients with infarction and TIA in carotid territory during and after anticoagulant therapy. Stroke 1979;10:529-32.
124. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJM, Brand R, Terpstra JL. Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia. Stroke 1993;24:1655-63.
125. Petty GW, Lennihan L, Mohr JP, Hauser WA, Weitz J, Owen J, et al. Complications of longterm anticoagulation. Ann Neurol 1988;23: 570-1.
126. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of longterm oral anticoagulant therapy. Arch Intern Med 1988;148:1733-6.
127. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications of oral anticoagulant therapy: Multivariate analysis of 1010 treatment yean in 551 outpatients. J Intern Med 1991;229:351-5.
128. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of 6 weeks with 6 months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
129. Moriyasu H, Yasaka M, Oita J, Yamaguchi T. Warfarin therapy for secondary prevention of cardioembolic stroke with nonvalvular atrial fibrillation: A retrospective study. Rinsho Shinkeigaku 1993;33:850-5.
130. Roy D, Marchand E, Gagne P, Chabot M, Carter R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986;112:1039-43.
131. Kase CS, Robinson RK, Stein RW, deWitt LD, Heir DB, Harp DL, et al. Anticoagulant-related intracerebral hemorrhage. Neurology 1985; 35:943-8.
132. Mathiesen T, Benediktsdottir K, Johnsson H, Lindquist M, von Holst H. Intracranial traumatic and nontraumatic hemorrhagic complications of warfarin treatment. Acta Neurol Scand 1995;91: 208-14.
133. Fredricksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23:972-7.
134. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
135. Wintzen AR, Tijssen JGP. Subdural hematoma and oral anticoagulant therapy. Arch Neurol 1982;39:69-72.
136. Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe KF. Anticoagulation-related intracranial extracerebral hemorrhage. J Neurol Neurosurg Psychiatry 1989;52:829-37.
137. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992;152:278-82.
138. Foulis PR, Wallach PM, Adelman HM, Sanford BH, McCain J, Reed D, et al. Performance of the Coumatrak system in a large anticoagulant clinic. Am J Clin Pathol 1995;103:98-102.
139. Le DT, Weibert RT, Sevilla DK, Donnelly KJ, Rapaport SI. The INR for monitoring warfarin therapy: Reliability and relation to other monitoring methods. Ann Intern Med 1994;120:552-8.
140. McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. Arch Intern Med 1992; 152:589-92.
141. Bussey HI, Chiquette E, Bianco TM, Bender K, Kraynak M, Farnett LE, et al. Superiority of fingerstick to routine laboratory prothrombin time determinations. Pharmacotherapy 1995;15:108.
142. Shorr RI, Ray WA, Daugherty JR, Griffen MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
143. Respond RM, Quandt CM, Clark GM, Bussey HI. Evaluation of factors associated with stability of anticoagulation therapy. Pharmacotherapy 1989;9:207-13.
144. Whitling AM, Chiquette E, Lyons RM, Bussey HI. Reversing over-anticoagulation: A comparison of subcutaneous or low-dose intravenous vitamin K to higher intravenous doses [abstract]. Pharmacotherapy 1996;16:145.
145. Carr MM, Mason RB. Dental management of anticoagulated patients. J Can Dent Assoc 1992;58:838-44.
146. Wilt VM, Gums JG, Ahmed OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995; 15:732-9.
147. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with routine medical care. Circulation 1995;92(Suppl): I-686.